Orexo enters into collaboration with Abera to develop nasal powder vaccines based on the AmorphOX technology

Orexo Sweden

The collaboration is in line with Orexo's strategy to broaden the use of its powder-based drug delivery technology AmorphOX®.Abera is a developer of mucosal vaccines and has several preclinical vaccine candidates based on Abera's innovative vaccine platform.The AmorphOX technology has the potential to improve the stability and efficacy of Abera's vaccine candidates.View original content:https://www.prnewswire.co.uk/news-releases/orexo-enters-into-collaboration-with-abera-to-develop-nasal-powder-vaccines-based-on-the-amorphox-technology-302333487.html